CVACライブシグナル | Getagraph.comで利益を最大化

買う 107745 min ago

@ $3.41

発行日: 15 2月 2024 @ 05:58

リターン: -26.43%

前回のシグナル: 2月 14 - 23:30

前回のシグナル: 売る

リターン: -2.14 %

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:43):

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA)...

Stats
本日の出来高	364 699
平均出来高	796 498
時価総額	560.83M
EPS	$-0.240 ( 2023-11-14 )
次の収益日	( $-0.140 ) 2024-06-04
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.600
ATR14	$0.00500 (0.20%)

ボリューム相関

長: -0.05 (neutral)

短: -0.39 (neutral)

Signal:(55.846) Neutral

CureVac AG 相関

10 最も正の相関
BELFA	0.934
CVLT	0.929
BELFB	0.926
SPNS	0.922
EWZS	0.911
XP	0.91
PTC	0.91
GLDD	0.907
XOG	0.904
CSGP	0.903

10 最も負の相関
PAYS	-0.885
OBNK	-0.883
DTEA	-0.882
CIDM	-0.869
TRMD	-0.866
PLXP	-0.862
AY	-0.847
NLSP	-0.847
EDRY	-0.845
JRSH	-0.844

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

CureVac AG 相関 - 通貨/商品

-0.46
( neutral )

-0.42
( neutral )

0.00
( neutral )

-0.17
( neutral )

-0.61
( weak negative )

-0.65
( weak negative )

CureVac AG 財務諸表

Annual	2023
収益:	$52.70M
総利益:	$-268.58M (-509.67 %)
EPS:	$0

FY	2023
収益:	$52.70M
総利益:	$-268.58M (-509.67 %)
EPS:	$0

FY	2022
収益:	$67.42M
総利益:	$-116.57M (-172.91 %)
EPS:	$-1.320

FY	2021
収益:	$102.99M
総利益:	$-135.21M (-131.28 %)
EPS:	$-2.28

Financial Reports:

No articles found.

CureVac AG

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. The company was founded in 2000 and is headquartered in Tübingen, Germany.